These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
175 related articles for article (PubMed ID: 32746796)
1. Risk of second primary malignancy in adults with pulmonary high-grade neuroendocrine carcinoma (HGNEC). Wu X; Zhang X; Tao L; Chen P BMC Cancer; 2020 Aug; 20(1):719. PubMed ID: 32746796 [TBL] [Abstract][Full Text] [Related]
2. The Risk of Second Primary Malignancies in Patients With Lung Neuroendocrine Tumors: A Population-Based Study on SEER Database. Bu X; Wang X; Wei L; Liu J; Chen M Curr Probl Cancer; 2020 Dec; 44(6):100613. PubMed ID: 32563531 [TBL] [Abstract][Full Text] [Related]
3. Exploring the risk of second primary malignancies in laryngeal cancer survivors: insights from the SEER database. Afify AY; Ashry MH Eur Arch Otorhinolaryngol; 2024 Aug; 281(8):4409-4417. PubMed ID: 38775833 [TBL] [Abstract][Full Text] [Related]
4. Risk of Second Primary Malignancies in Patients With Follicular Lymphoma: A United States Population-based Study. Giri S; Bhatt VR; Verma V; Pathak R; Bociek RG; Vose JM; Armitage JO Clin Lymphoma Myeloma Leuk; 2017 Sep; 17(9):569-574. PubMed ID: 28709798 [TBL] [Abstract][Full Text] [Related]
5. Clinicopathological significance of cancer stem-like cell markers in high-grade neuroendocrine carcinoma of the lung. Morise M; Hishida T; Takahashi A; Yoshida J; Ohe Y; Nagai K; Ishii G J Cancer Res Clin Oncol; 2015 Dec; 141(12):2121-30. PubMed ID: 25963795 [TBL] [Abstract][Full Text] [Related]
6. Trends in the risk and burden of second primary malignancy among survivors of smoking-related cancers in the United States. Adjei Boakye E; Buchanan P; Hinyard L; Osazuwa-Peters N; Simpson MC; Schootman M; Piccirillo JF Int J Cancer; 2019 Jul; 145(1):143-153. PubMed ID: 30613963 [TBL] [Abstract][Full Text] [Related]
7. The Incidence Characteristics of Second Primary Malignancy after Diagnosis of Primary Colon and Rectal Cancer: A Population Based Study. Guan X; Jin Y; Chen Y; Jiang Z; Liu Z; Zhao Z; Yan P; Wang G; Wang X PLoS One; 2015; 10(11):e0143067. PubMed ID: 26571301 [TBL] [Abstract][Full Text] [Related]
8. A pilot study of adjuvant chemotherapy with irinotecan and cisplatin for completely resected high-grade pulmonary neuroendocrine carcinoma (large cell neuroendocrine carcinoma and small cell lung cancer). Kenmotsu H; Niho S; Ito T; Ishikawa Y; Noguchi M; Tada H; Sekine I; Watanabe S; Yoshimura M; Yamamoto N; Oshita F; Kubota K; Nagai K Lung Cancer; 2014 Jun; 84(3):254-8. PubMed ID: 24679951 [TBL] [Abstract][Full Text] [Related]
9. Ubiquitin C-terminal hydrolase-L1 has prognostic relevance and is a therapeutic target for high-grade neuroendocrine lung cancers. Shimada Y; Kudo Y; Maehara S; Matsubayashi J; Otaki Y; Kajiwara N; Ohira T; Minna JD; Ikeda N Cancer Sci; 2020 Feb; 111(2):610-620. PubMed ID: 31845438 [TBL] [Abstract][Full Text] [Related]
10. Risk of second primary malignancies in survivors of pancreatic neuroendocrine neoplasms from 2000 to 2018. Yang Z; Liu L; Leng K; Shi G J Gastroenterol Hepatol; 2023 Sep; 38(9):1474-1484. PubMed ID: 37114675 [TBL] [Abstract][Full Text] [Related]
11. Malignancies diagnosed before and after anal squamous cell carcinomas: A SEER registry analysis. Jani KS; Lu SE; Murphy JD; Romesser PB; Jethwa KR; Li D; Chundury A; Wu AJ; Hathout L; Hallemeier CL; Jabbour SK Cancer Med; 2021 Jun; 10(11):3575-3583. PubMed ID: 33960690 [TBL] [Abstract][Full Text] [Related]
12. Clinical features of unresectable high-grade lung neuroendocrine carcinoma diagnosed using biopsy specimens. Shimada Y; Niho S; Ishii G; Hishida T; Yoshida J; Nishimura M; Yoh K; Goto K; Ohmatsu H; Ohe Y; Nagai K Lung Cancer; 2012 Mar; 75(3):368-73. PubMed ID: 21920624 [TBL] [Abstract][Full Text] [Related]
13. Risk of second primary malignancy in patients with sinonasal tumors: a population-based cohort study. Ganti A; Plitt MA; Kuan EC; Kuhar HN; Batra PS; Tajudeen BA Int Forum Allergy Rhinol; 2018 Jun; 8(6):756-762. PubMed ID: 29381260 [TBL] [Abstract][Full Text] [Related]
14. Combined high-grade neuroendocrine carcinoma of the lung: clinicopathological and immunohistochemical study of 34 surgically resected cases. Yamada K; Maeshima AM; Tsuta K; Tsuda H Pathol Int; 2014 Jan; 64(1):28-33. PubMed ID: 24471967 [TBL] [Abstract][Full Text] [Related]
15. High-Grade Neuroendocrine Carcinoma with Bronchial Intraepithelial Tumor Spread: Possibly a New Histologic Feature of Large-Cell Neuroendocrine Carcinoma. Kojima H; Watanabe R; Isaka M; Shimizu R; Kayata H; Miyata N; Maniwa T; Takahashi S; Ito I; Kameya T; Funai K; Ohde Y; Nakajima T J Thorac Oncol; 2015 Sep; 10(9):1337-1340. PubMed ID: 26291012 [TBL] [Abstract][Full Text] [Related]
16. Second Primary Malignant Neoplasms and Survival in Adolescent and Young Adult Cancer Survivors. Keegan THM; Bleyer A; Rosenberg AS; Li Q; Goldfarb M JAMA Oncol; 2017 Nov; 3(11):1554-1557. PubMed ID: 28426850 [TBL] [Abstract][Full Text] [Related]
17. Elevated risk of human papillomavirus-related second cancers in survivors of anal canal cancer. Nelson RA; Lai LL Cancer; 2017 Oct; 123(20):4013-4021. PubMed ID: 28608917 [TBL] [Abstract][Full Text] [Related]
18. Second Primary Malignancies of the Bones and Joints: More Common than Expected in Osteosarcoma Patients. Freedman IG; Dowd HN; Dhodapkar MM; Halperin SJ; Grauer JN J Am Acad Orthop Surg Glob Res Rev; 2023 Jan; 7(1):. PubMed ID: 36695170 [TBL] [Abstract][Full Text] [Related]
19. Second Primary Malignancy in Bladder Carcinoma - A Population-based Study. Khanal A; Budhathoki N; Singh VP; Shah BK Anticancer Res; 2017 Apr; 37(4):2033-2036. PubMed ID: 28373478 [TBL] [Abstract][Full Text] [Related]
20. Prognostic impact of interstitial lung disease on pulmonary high-grade neuroendocrine carcinoma. Sakai T; Azuma Y; Kusano M; Kato S; Koezuka S; Iyoda A Sci Rep; 2024 Sep; 14(1):21274. PubMed ID: 39261570 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]